Brooks Laboratories Ltd. (NSE: BROOKS, BSE: 533543) is a Mumbai, Maharashtra-based company in the Life Sciences Tools and Services industry. With a market capitalisation of ₹199 Cr, it ranks #2,668 by market cap among the 6,137 Indian listed companies on FinBizNet, and #6 of 10 in Life Sciences Tools and Services. At ₹57.86 (as of 25 Oct 2026), the share price is 53.0% below its 52-week high of ₹123.00 and 59.4% above its 52-week low of ₹36.30. The share price is down 53.0% over one year and down 9.7% over three months.
| Current Price | ₹57.86 |
|---|---|
| Market Cap | ₹199 Cr |
| NSE Symbol | BROOKS |
| BSE Code | 533543 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services |
| P/E Ratio | 8.1 |
| Return on Equity | 22.28% |
| Return on Assets | 2.77% |
| 52-Week Range | ₹36.30 – ₹123.00 |
| 1-Year Price Change | -53.0% |
| 3-Month Price Change | -9.7% |
| Beta (1Y) | 1.08 |
| Headquarters | Mumbai, Maharashtra |
| Website | www.brookslabs.net |
| Revenue | ₹23 Cr |
|---|---|
| Net Profit | ₹1 Cr |
| Net Margin | 6.2% |
| EPS (Basic) | ₹-0.61 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Brooks Laboratories Limited provides contract development and manufacturing services for pharmaceutical companies in India and internationally. The company’s product portfolio includes liquid injection ampoules and vials, dry powder injection vials, lyophilized injections, eye/ear drops, and nasal drops; B-Lactam and cephalosporin tablets, dry powder syrups, and injections; general, liquid, and dry powder injections; formulations for antibiotics, pain management, and controlled drugs; and oncology products and hormonal injections, etc. It also provides regulatory compliance, custom branding and packaging, scalable production, and end-to-end support services. The company serves government health programs and public sector institutions, hospitals and medical colleges, defense and railways, corporate healthcare, and NGOs. It exports its products to Afghanistan, Yemen, Kosovo, Bolivia, Guatemala, Turkmenistan Nigeria, Lebanon, Mauritius, Sudan, Madagascar, DR Congo, Mozambique, LATAM, and
1. Pharmaceuticals-This segment is engaged in manufacturing various pharmaceutical formulations.
1. Trading-3.3% 2. Manufacturing-96.7%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Indegene Ltd | ₹14,413 Cr | 35.2 | 13.94% | ₹1,063 Cr | +5.9% |
| Suven Life Sciences Ltd. | ₹8,583 Cr | -24 | -78.80% | ₹4 Cr | +30.6% |
| Vimta Labs Ltd | ₹2,338 Cr | 29.3 | 18.55% | ₹109 Cr | -32.5% |
| Tarsons Products Limited | ₹1,762 Cr | 117.2 | 2.26% | ₹110 Cr | +3.3% |
| Bilcare Ltd. | ₹224 Cr | 122.4 | -5.21% | — | — |
| Brooks Laboratories Ltd. | ₹199 Cr | 8.1 | 22.28% | ₹23 Cr | -53.0% |
| Jeevan Scientific Technology Ltd | ₹178 Cr | 130.4 | 1.68% | — | +34.0% |
| Vivo Bio Tech Ltd. | ₹31 Cr | -16.6 | -2.00% | ₹14 Cr | -55.7% |
| Dr. Habeebbullal Life Sciences Ltd | ₹28 Cr | -2.8 | -68.79% | — | -32.7% |
Listed by market capitalisation. Ratios are shown for context only.
Brooks Laboratories Ltd. is trading at ₹57.86, with a market capitalisation of ₹199 Cr.
Brooks Laboratories Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services).
Brooks Laboratories Ltd. has a P/E of 8.1 and a return on equity of 22.28%.
Brooks Laboratories Ltd. is listed on the NSE under the symbol BROOKS and on the BSE under the scrip code 533543.
Brooks Laboratories Ltd.'s share price is down 53.0% over one year and down 9.7% over three months. Its 52-week range is ₹36.30 to ₹123.00.
In Q1 FY27, Brooks Laboratories Ltd. reported revenue of ₹23 Cr and net profit of ₹1 Cr, with basic EPS of ₹-0.61 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.